A phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response

BACKGROUND: Central nervous system (CNS) metastases develop in nearly half of patients with advanced melanoma and in 15–20% CNS is the first site of relapse. Median overall survival is short, ranging from two to four months, and one-year survival rate is only 10–15%. THA has been shown to have both...

Descripción completa

Detalles Bibliográficos
Autores principales: Vestermark, LW, Holtved, E, Dahlrot, R, Brimnes, MK, Svane, IM, Bastholt, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234039/
https://www.ncbi.nlm.nih.gov/pubmed/22275974
http://dx.doi.org/10.3332/ecancer.2008.91

Ejemplares similares

Ejemplares similares